ReviewFrontiers in oncology2013
Current status and evolution of preclinical drug development models of epithelial ovarian cancer.
Review in Frontiers in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer.Cancer letters · 2025Article
- Nanoparticle-Encapsulated Epirubicin Efficacy in the Inhibition of Growth of Orthotopic Ovarian Patient-Derived Xenograft in Immunocompromised Mice.International journal of molecular sciences · 2024Article
- Article
- Article
- The hallmarks of ovarian cancer: proliferation and cell growth.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2020Article
- MiR-140-3p inhibits natural killer cytotoxicity to human ovarian cancer via targeting MAPK1.Journal of biosciences · 2020Article
- Characteristics of in Vivo Model Systems for Ovarian Cancer Studies.Diagnostics (Basel, Switzerland) · 2019Review
- β-hCG promotes epithelial ovarian cancer metastasis through ERK/MMP2 signaling pathway.Cell cycle (Georgetown, Tex.) · 2019Article
- Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.Cancer immunology, immunotherapy : CII · 2018Article
- A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.Oncotarget · 2017Article
- Precision targeted therapy of ovarian cancer.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.Journal of translational medicine · 2016Article
- HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer.Frontiers in oncology · 2016Review
- An Advanced Orthotopic Ovarian Cancer Model in Mice for Therapeutic Trials.BioMed research international · 2016Article
- Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.Cancer medicine · 2015Article
- Orthotopic non-metastatic and metastatic oral cancer mouse models.Oral oncology · 2015Article
- Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy.American journal of cancer research · 2015Article
- Editorial: Advances in Epithelial Ovarian Cancer: Model Systems, Microenvironmental Influences, Therapy, and Origins.Frontiers in oncology · 2015Article
- Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and the fifth most common cause of female cancer death in the United States. Although important advances in surgical and chemotherapeutic strategies over the last three decades have significantly improved the median survival of EOC patients, the plateau of the survival curve has not changed appreciably. Given that EOC is a genetically and biologically heterogeneous disease, identification of specific molecular abnormalities that can be targeted in each individual ovarian cancer on the basis of predictive biomarkers promises to be an effective strategy to improve outcome in this disease. However, for this promise to materialize, appropriate preclinical experimental platforms that recapitulate the complexity of these neoplasms and reliably predict antitumor activity in the clinic are critically important. In this review, we will present the current status and evolution of preclinical models of EOC, including cell lines, immortalized normal cells, xenograft models, patient-derived xenografts, and animal models, and will discuss their potential for oncology drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.